Cure

Music can ease the January blues – but the types of songs that work depend on your age and mindset

Retrieved on: 
Martedì, Gennaio 16, 2024
Noise, Patient, Trauma, Research, Weight loss, Sadness, Happiness, Mental health, Anxiety, Cure, Emotion, Exercise, Sensation, Pleasure, Catharsis, Music

So what type of music should you turn to in order to boost your mood?

Key Points: 
  • So what type of music should you turn to in order to boost your mood?
  • But, as illogical as it may seem, that sensation of sadness may actually help lead to positive emotions.
  • For example, our preference for classical music increases as we age while our preference for rock decreases.
  • But further findings have shown that a listener’s age can also affect the types of music that improve their low mood.

Biotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as Partners

Retrieved on: 
Lunedì, Gennaio 8, 2024
Biotechnology, Finance, Health, Professional Services, Asset Management, Ionis Pharmaceuticals, Science, Cure, Drug discovery, Partner, Pramipexole, UC, Juno Therapeutics, Forest Laboratories, DSM-IV codes, Heart, Therapy, Memantine, Growth, Central nervous system, Patient, Organization, Harvard Medical School, Biogen, University of California, Irvine, Pharmaceutical industry

Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.

Key Points: 
  • Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.
  • and Al Robichaud, Ph.D. as partners to expand the firm’s work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases.
  • It’s clear to me that Cure has the chops to strategically choose its partners and elevate their work.
  • More importantly, he is about as well respected a leader as you can find in our industry,” said Dave Fallace, co-founder and managing partner at Cure Ventures.

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Retrieved on: 
Giovedì, Gennaio 4, 2024
Research, Neurology, Diabetes, Clinical Trials, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Conference, Cure, IND, SAPPHIRE, Spinal muscular atrophy, Clinical trial, Obesity, Standard of care, Annual general meeting, Gongshi, Consequence, Myostatin, DRAGON, Webcast, MPH, Patient, Rock, SMN, SMA, Renal cell carcinoma, SITC, Pharmaceutical industry

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
  • Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
  • Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Zhihu Announces Receipt of NYSE Notification Regarding ADS Trading Price Requirement

Retrieved on: 
Venerdì, Dicembre 29, 2023
ADS, Cure, Calendar, Letter, Medical device

The NYSE notification does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or contractual obligations.

Key Points: 
  • The NYSE notification does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or contractual obligations.
  • Once notified by the NYSE, the Company must bring its security price and average security price back above US$1.00 by six months (the "Cure Period") following receipt of the notification.
  • In the event that at the expiration of the Cure Period, both a US$1.00 per ADS closing price on the last trading day of the Cure Period and a US$1.00 per ADS average closing price over the 30 trading-day period ending on the last trading day of the Cure Period are not attained, the NYSE will commence suspension and delisting procedures.
  • As required by the NYSE Listed Company Manual, the Company expects to notify the NYSE of its intent to cure its ADS trading price deficiency within the applicable time period required by the NYSE.

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Retrieved on: 
Martedì, Dicembre 19, 2023
CSF, Patient, Nosebleed, Cure, Risk, Șaeș, Interest, Pulmonary embolism, PIN, Depression, FRCP, Headache, TMS, CHDI, Brain, Neurofilament, SAE, Clinical trial, TFC, Natural history, Event, Inflammation, Hypothermia, AFL, University College London, Biomarker, Back pain, Suicidal ideation, Central nervous system, Frasier, Deep vein thrombosis, UCL, Pharmaceutical industry

The U.S. study consists of a blinded 12-month core study period followed by unblinded long-term follow-up of five years for treated patients.

Key Points: 
  • The U.S. study consists of a blinded 12-month core study period followed by unblinded long-term follow-up of five years for treated patients.
  • Six patients were treated with AMT-130 in the initial low-dose cohort and seven patients were treated in the subsequent high-dose cohort.
  • The cohort includes 31 patients that met the uniQure clinical trial inclusion criteria of Total Functional Capacity, Diagnostic Classification Level and minimum striatal volumes.
  • In mid-2024, uniQure expects to present another clinical update from the ongoing Phase I/II studies of AMT-130, including additional follow-up data from the treated patients in the U.S. and European trials.

New study finds the majority of cancer patients use online resources at least several times a week to manage their care

Retrieved on: 
Martedì, Dicembre 19, 2023
Patient, Roger Hawkins (drummer), Breast cancer, Physician, Data analysis, Estate (law), Cancer, Empowerment, Cure, Face, Overalls, Inc., Pharmaceutical industry

BOSTON, Dec. 19, 2023 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first direct-to-patient, personalized, and evidence-based cancer navigation platform, announced today the results of its second annual State of Patient Empowerment Report. The report is based upon a survey of more than 450 breast cancer patients and data from more than 850 medical records requests across 667 medical centers in every U.S. state. The study uncovered that only half of patients (51%) felt their care team was fully accessible to answer questions during active treatment and only a third of patients were fully satisfied with the information they received from their care team during both active treatment and survivorship.

Key Points: 
  • Patients remain at a disadvantage if they rely solely upon their provider for information to guide their care.
  • Strains on the healthcare system and staffing challenges within the oncology workforce, combined with the fact that the majority of cancer patients receive their care in a community-oncology setting, lead to significant knowledge disparities among cancer patients."
  • Information and access gaps are driving self-advocacy online: 69% of patients use online resources at least several times a week to manage their care, while 34% of patients sought a second opinion from another provider.
  • Additionally, more than half of patients would be willing to share their medical records with an online platform if doing so would help them to manage their cancer care.

New study finds the majority of cancer patients use online resources at least several times a week to manage their care

Retrieved on: 
Martedì, Dicembre 19, 2023
Patient, Roger Hawkins (drummer), Breast cancer, Physician, Data analysis, Estate (law), Cancer, Empowerment, Cure, Face, Overalls, Inc., Pharmaceutical industry

BOSTON, Dec. 19, 2023 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first direct-to-patient, personalized, and evidence-based cancer navigation platform, announced today the results of its second annual State of Patient Empowerment Report. The report is based upon a survey of more than 450 breast cancer patients and data from more than 850 medical records requests across 667 medical centers in every U.S. state. The study uncovered that only half of patients (51%) felt their care team was fully accessible to answer questions during active treatment and only a third of patients were fully satisfied with the information they received from their care team during both active treatment and survivorship.

Key Points: 
  • Patients remain at a disadvantage if they rely solely upon their provider for information to guide their care.
  • Strains on the healthcare system and staffing challenges within the oncology workforce, combined with the fact that the majority of cancer patients receive their care in a community-oncology setting, lead to significant knowledge disparities among cancer patients."
  • Information and access gaps are driving self-advocacy online: 69% of patients use online resources at least several times a week to manage their care, while 34% of patients sought a second opinion from another provider.
  • Additionally, more than half of patients would be willing to share their medical records with an online platform if doing so would help them to manage their cancer care.

Wandercraft, pioneer of walking robotics, opens U.S. corporate headquarters at Cure®, New York City's premier healthcare innovation campus

Retrieved on: 
Martedì, Dicembre 12, 2023
European Economic Area, Gait, Research, Engineering, Food, Organization, Tetraplegia, Spasm, Patient, Heart, FDA, Wheelchair, Movement, Health, Rehabilitation, Therapy, Neuroscience, Multiple sclerosis, Atalante, Pain, Walking, SCI, Deep vein thrombosis, Pharmaceutical industry, Medical device, Stroke, Cure

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Wandercraft, developer of the world's first in market self-stabilizing exoskeleton designed to enable people with walking impairments to stand and walk again, announced today the opening of its U.S. headquarters at Cure®, a healthcare innovation campus in New York City. The Company now has headquarters both in the U.S. where its CEO Matthieu Masselin has relocated, and in France where it originated, after receiving clearance from the U.S. Food and Drug Administration in early 2023 for its lead product, the hands-free Atalante X™ exoskeleton, for use in stroke rehabilitation.

Key Points: 
  • ET on Wednesday, Dec. 13 at Cure, 345 Park Avenue South, New York City.
  • The event will include demonstrations of its new Personal Exoskeleton that will offer new, revolutionary options to those of us in wheelchairs.
  • Wandercraft is joining Cure's group of start-up and established companies that have collectively raised more than $760 million since 2021.
  • The campus community offers residents opportunities to create synergies and collaborative partnerships with peer organizations that span medical technology, healthcare services, therapeutics, healthcare investment, academic research and non-profit initiatives.

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

Retrieved on: 
Lunedì, Dicembre 11, 2023
Actinium, NYSE, DCR, ASH, Acute myeloid leukemia, BMT, Patient, Haematopoietic system, Cure, Hematology, Survival, AML, Rated R, Society, TP53, Mutation

The oral presentation highlighted significantly improved survival in patients with a TP53 mutation receiving Iomab-B.

Key Points: 
  • The oral presentation highlighted significantly improved survival in patients with a TP53 mutation receiving Iomab-B.
  • Iomab-B is a targeted radiotherapeutic comprised of an anti-CD45 monoclonal antibody with the Iodine-131 radioisotope payload.
  • In addition, Iomab-B significantly improved event-free survival, a secondary endpoint, with a hazard ratio of 0.22 and median overall survival (mOS) was doubled.
  • Data highlighted in the ASH oral presentation, which can be accessed on the investor relations page of Actinium's website, included:
    Overall Survival in Patients with a TP53 Mutation:

Expro Completes Well Cementing Project in the Deepwater US Gulf of Mexico

Retrieved on: 
Martedì, Novembre 7, 2023
Alternative Energy, Energy, Other Energy, Oil, Gas, Well, Security (finance), Cure, Water, NYSE, Form, Acquisition, Multimedia, Growth, Risk, 8-K, Safety, WOC, Environmental remediation, Expro, Mississippi Canyon

View the full release here: https://www.businesswire.com/news/home/20231107005904/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231107005904/en/
    Expro's Innovative cement placement technologies support subsea well safety and operational efficiency.
  • (Photo: Business Wire)
    Expro's Cure technologies allowed the operator to overcome ongoing offset well challenges.
  • The DeltaTek range of low-risk open water cementing solutions help increases clients’ operational efficiency, delivers rig time and cost savings, and improves the quality of cementing operations.
  • The Company’s extensive portfolio of capabilities spans well construction, well flow management, subsea well access, and well intervention and integrity solutions.